Shanshan He

Shanshan He

Auto-generated profile, based on publicly available information

Shanshan He

The Department of Oncoplastic Breast Surgery Tianjin Medical University Cancer Institute and Hospital Tianjin China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in JPRAS Open
Verified
Journal Article
Open access
SWS. Wang
S. Wang
SHS. He
S. He
XZX. Zhang
X. Zhang
JSJ. Sun
J. Sun
QHQ. Huang
Q. Huang
JYJ Yin
J Yin
Acellular Bovine Pericardium Matrix (ABPM) is a new material in implant-based breast reconstruction (IBBR). Few studies have reported on its outcome and complications worldwide and most studies were without a control group. Our aim was to compare its use in IBBR with the other two conventional implant-based reconstruction methods. A retrospective review of patients undergoing IBBR from January to December 2018 was performed. Patients were assigned to the ABPM-assisted IBBR (group A), latissimus dorsi-assisted IBBR (group B) and two-stage IBBR (group C). Patients’ post-operative complications, cost-effectiveness and Quality of Life were compared. 100 patients with 100 breasts were included in the study. No complications occurred in group C (n = 11). No significant differences were noted between group A (n = 44) and group B (n = 45) in terms of overall complications (9.1% vs 11.1%, p = 0.973). Group B had the longest operative duration (310.8 ± 62.3 min, p<0.001). The cost of hospitalization forthe three groups was $8051.3 ± 849.2, $7566.0 ± 1172.7 and $7896.5 ± 1762.2, respectively (p = 0.128). The postoperative Breast-Q scores were similar across the three groups. ABPM demonstrated acceptable complication rates, cost-effectiveness and quality of life outcomes when compared to LD-assisted IBBR and two-stage IBBR.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
MSMary Stackpole
Mary Stackpole
WZWeihua Zeng
Weihua Zeng
SLShuo Li
Shuo Li
CLChun-Chi Liu
Chun-Chi Liu
YZYonggang Zhou
Yonggang Zhou
XZXianghong Jasmine Zhou
Xianghong Jasmine Zhou
Early cancer detection by cell-free DNA (cfDNA) faces multiple challenges: the low fraction of tumor DNA in cfDNA, the molecular heterogeneity of cancer, and sample sizes that are too small to reflect the heterogeneous patient population. We have developed an integrated cancer detection system, CancerRadar, that addresses all three challenges. It consists of (1) a cost-effective experimental assay, cfMethyl-Seq, for genome-wide methylation profiling of cfDNA, which provides >12-fold enrichment over Whole Genome Bisulfite Sequencing (WGBS) in CpG islands; and (2) a computational platform to extract information from cfMethyl-Seq data and diagnose the patient. The platform derives cfDNA methylations, cfDNA fragment sizes, copy number variations (CNV), and microbial composition from the raw cfMethyl-Seq data, and performs multi-feature ensemble learning. We demonstrate the power of CancerRadar by detecting and locating cancer in a cohort of 275 colon, liver, lung, and stomach cancer patients and 204 non-cancer individuals. For cancer detection, we achieve a sensitivity of 85.6%± 6.7% across all stages and 80.6%±9.1% for early stages (I and II), with a specificity of 99% in both cases. These metrics are derived using leave-one-out cross-validation. During independent validation on a reserved subsample, it achieves a sensitivity of 89.1%±11.3% across all stages and 85.7%±14.2% for early stages, with a specificity of 97% (one false positive). For locating a tumor's tissue of origin (TOO), CancerRadar achieved an accuracy of 91.5%±5.0% for all stages and 89.1%±7.3% for early stages, on an independent subsample. This study is the first to integrate cfDNA methylation, cfDNA fragment size, CNV, and microbial composition analyses for cancer detection on the same patient cohort. cfDNA methylation was the most useful for detecting cancer, but including features from other categories significantly increased the performance, especially for early-stage cancer. In contrast, with respect to TOO prediction, methylation-derived features were overwhelmingly important while including other features did not further improve performance. To fully exploit the power of cfDNA methylation, we identified four types of methylation markers with different characteristics. We have also improved our previous read-level deconvolution algorithm to more accurately identify trace tumor signals. Finally, our data show that as training sample sizes increase, the detection power of CancerRadar continues to increase. Although all existing cancer detection studies are limited by training sample sizes, the CancerRadar system uniquely and cost-effectively retains the genome-wide epigenetic and genetic profiles of cancer abnormalities, thereby permitting the classification models to learn and exploit newly significant features as training cohorts grow, as well as expanding their scope to other cancer types. Citation Format: Mary Stackpole, Weihua Zeng, Shuo Li, Chun-Chi Liu, Yonggang Zhou, Shanshan He, Angela Yeh, Ziye Wang, Fengzhu Sun, Qingjiao Li, Zuyang Yuan, Asli Yildirim, Pin Jung Chen, Paul Winograd, Shize Li, Zorawar Noor, Edward Garon, Samuel French, Clara Magyar, Sarah Dry, Clara Lajonchere, Daniel Geschwind, Gina Choi, Sammy Saab, Frank Alber, Wing Hung Wong, Steven Dubinett, Denise Aberle, Vatche Agopian, Steven-Huy Han, Xiaohui Ni, Wenyuan Li, Xianghong Jasmine Zhou. Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 24.

1 November 2020 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
LYLian Yan
Lian Yan
WLWenjuan Li
Wenjuan Li
SHShanshan He
Shanshan He
AMAifeng Meng
Aifeng Meng
JLJianhong Liu
Jianhong Liu
JZJianmei Zhou
Jianmei Zhou
Background: To explore adverse drug reactions (ADRs) and the effects of nursing interventions after Aidi injection for the treatment of non-Hodgkin’s lymphoma (NHL). Methods: A total of 104 NHL patients treated in our hospital from March 2019 to March 2020 were selected. All patients underwent conventional chemotherapy, with a concomitant Aidi injection administered at different doses (40, 60, 80, and 100 mL). ADRs were analyzed for all patients, and the clinical outcomes of ADRs were recorded after specific nursing interventions were performed. Results: A total of 17 NHL patients had ADRs, with a total incidence rate of 15.89% (total of 30 ADRs). In terms of different types of ADRs, inappetence accounted for the largest proportion, followed by skin pruritus and fever, phlebitis, nausea and vomiting, and chest distress and/or palpitation, the last of which shared the same proportion as chills and/or low fever and urticaria. The incidence rate of ADRs (total of 18 ADRs, 60.00%) was higher in NHL patients who were given 100 mL of Aidi injection. In terms of age and gender distribution of ADRs, there were 10 males (55.56%) and 7 females (44.44%), and ADRs were more common in patients aged 46-60 years old (total of 6 ADRs, 35.29%). Aidi injection mainly induced mild ADRs (total of 22 ADRs, 73.33%), and the resulting ADRs mostly occurred for <2 hours (total of 19 ADRs, 60.00%). After the specific nursing interventions were performed, no deaths due to ADRs occurred, and 12 (64.71%) cases were cured, 5 (29.41%) cases improved, and 1 (5.88%) case had no progression. Conclusions: Particular attention should be paid to ADRs in the treatment of NHL patients with Aidi injection. After ADRs occur, specific nursing interventions can aid in recovery and lead to improvements in prognosis.

3 October 2026 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
CSCong Su
Cong Su
SWShu Wang
Shu Wang
SHShanshan He
Shanshan He
WZWeiqing Zhao
Weiqing Zhao
JYJian Yin
Jian Yin